We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Collaborative Agreement Focuses on Development of Small-Molecule Therapeutics for Leukemia and Other Cancers

By LabMedica International staff writers
Posted on 28 Mar 2016
A collaborative agreement between a renowned American university-based research institute and one of the largest pharmaceutical companies in the world will focus on the development of small-molecule therapeutics for leukemia and other cancers.

Harvard University (Cambridge, MA, USA) has entered into an exclusive license and research collaboration agreement with Merck (Kenilworth, NJ, USA) to exploit novel compounds that had been developed in research laboratories at Harvard. More...
These compounds offer an innovative approach to cancer treatment, targeting enzymes that regulate transcription.

Merck will be responsible for development of the candidate therapeutics and will engage in a research collaboration Harvard to further investigate the biology of transcriptional regulator enzymes.

Under the terms of the license agreement, Merck will pay Harvard an up-front fee of 20 million USD and will be responsible for development, including clinical development, and for worldwide commercialization of products. Harvard University will also be eligible to receive development and commercialization milestone payments, as well as tiered royalties on any resulting products.

“Accelerator funding over the course of several years has enabled my laboratory to advance some of our experimental compounds to a relatively late stage of preclinical development,” said Dr. Matthew Shair, professor of chemistry and chemical biology at Harvard University. “It is gratifying to have discovered a new biological target in the fight against acute myeloid leukemia (AML), but even more fulfilling to have created a promising weapon against it.”

“This recent agreement with the Shair laboratory is rooted in our belief that collaboration is the cornerstone for improving cancer care and driving innovation. It is the partnership among industry and academia that is truly critical to transforming cancer treatment and advancing the care for patients with difficult-to-treat blood cancers, such as acute myeloid leukemia,” said Dr. Eric Rubin, vice president and therapeutic area head, oncology early stage development at Merck Research Laboratories.

“University researchers bring a great degree of creativity and innovation to the toughest challenges in human medicine,” said Isaac T. Kohlberg, senior associate provost and chief technology development officer at Harvard University. “Professor Shair’s inventive leukemia research has reached a stage of development that is unusual in most universities but of great interest to the health care industry and ultimately to patients. His work could change the way clinicians treat a major disease.”

Related Links:

Harvard University 
Merck



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.